Research

Hormonal

GLP-1 receptor agonist therapy is associated with significant gastrointestinal adverse events and weight regain upon discontinuation, limiting its long-term durability compared to surgery.

GLP-1 medications like semaglutide or liraglutide can help you lose 15-25% of your body weight, but you may experience nausea, vomiting, or digestive issues. Crucially, if you stop taking the medication, you are likely to regain the weight. Surgery offers more sustained weight loss and cardiovascular protection, though it involves surgical risks.

GoodQualifiesHIGH confidence
use of GLP-1 RAs associated with several GI adverse events, including nausea, vomiting, diarrhoea, constipation, gallbladder disorders such as cholelithiasis, and gastroesophageal reflux disease (GERD)... weight regain also reported after discontinuation of medication
Joshua Chadwick et al. · Obesity Surgery · 2026

Why this rating

Consistently reported across multiple studies and cited literature.

Source

Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis

Joshua Chadwick et al. · Obesity Surgery · 2026

DOI 10.1007/s11695-026-08508-5

Meta-analysis · 11 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →